ICHRA: The Next Big Thing?
Sam Bogrov·4 min
Excited to announce the $13M series A led by GV in Signos, which helps you lose weight through continuous glucose monitoring (CGM). Tau Ventures had first invested alongside Courtside Ventures and 1984.vc in the unannounced $4M seed. We are an AI-first fund in Silicon Valley investing primarily in seed and occasionally take later bets when we see immense promise. “Signos” has a number of meanings paying homage to the company’s mission. For instance in Spanish it means “signs” which evokes signals and communication to help you understand your body’s language. The company was founded in 2018 and impressed us with (1) a strong need, (2) building an execution-focused team, and (3) creating a differentiated product.
Technology can be a very powerful tool in any health journey -- I speak from personal experience of having lost 35 lbs a few years back, inspired greatly by cofounding a digital health company myself. There are many tech-enabled solutions to help with weight management but few give users the ability to truly understand what’s going inside your body. Signos’s value proposition is that CGMs can give those data-driven insights, especially when you eat, exercise or sleep. A CGM may not be for everyone, for instance, anyone has needle phobia, but there are enough people out there who would use it. Maintaining your blood sugar within a certain range is key to burning and not accumulating fat. The company’s focus is non-diabetics i.e., the vast majority of us, with the view that an action today can prevent problems tomorrow.
We are honored and excited to be part of Signos’s journey, using technology to solve a big problem. More at http://www.signos.com.
Instantly repurpose any DDI article into a professionally produced short-form video.
Try DDI Media →